Suppr超能文献

使用扁桃体来源的间充质干细胞进行无支架甲状旁腺组织工程

Scaffold-free parathyroid tissue engineering using tonsil-derived mesenchymal stem cells.

作者信息

Park Yoon Shin, Hwang Ji-Young, Jun Yesl, Jin Yoon Mi, Kim Gyungah, Kim Ha Yeong, Kim Han Su, Lee Sang-Hoon, Jo Inho

机构信息

Department of Molecular Medicine, School of Medicine, Ewha Womans University, Seoul 158-710, Republic of Korea; Ewha Tonsil-derived mesenchymal Stem cells Research Center (ETSRC), School of Medicine, Ewha Womans University, Seoul 158-710, Republic of Korea; School of Life Science, College of Natural Sciences, Chungbuk National University, Cheongju 361-763, Republic of Korea.

Department of Biomedical Engineering, College of Health Science, Korea University, Seoul 136-713, Republic of Korea.

出版信息

Acta Biomater. 2016 Apr 15;35:215-27. doi: 10.1016/j.actbio.2016.03.003. Epub 2016 Mar 2.

Abstract

UNLABELLED

To restore damaged parathyroid function, parathyroid tissue engineering is the best option. Previously, we reported that differentiated tonsil-derived mesenchymal stem cells (dTMSC) restore in vivo parathyroid function, but only if they are embedded in a scaffold. Because of the limited biocompatibility of Matrigel, however, here we developed a more clinically applicable, scaffold-free parathyroid regeneration system. Scaffold-free dTMSC spheroids were engineered in concave microwell plates made of polydimethylsiloxane in control culture medium for the first 7days and differentiation medium (containing activin A and sonic hedgehog) for next 7days. The size of dTMSC spheroids showed a gradual and significant decrease up to day 5, whereafter it decreased much less. Cells in dTMSC spheroids were highly viable (>80%). They expressed high levels of intact parathyroid hormone (iPTH), the parathyroid secretory protein 1, and cell adhesion molecule, N-cadherin. Furthermore, dTMSC spheroids-implanted parathyroidectomized (PTX) rats revealed higher survival rates (50%) over a 3-month period with physiological levels of both serum iPTH (57.7-128.2pg/mL) and ionized calcium (0.70-1.15mmol/L), compared with PTX rats treated with either vehicle or undifferentiated TMSC spheroids. This is the first report of a scaffold-free, human stem cell-based parathyroid tissue engineering and represents a more clinically feasible strategy for hypoparathyroidism treatment than those requiring scaffolds.

STATEMENT OF SIGNIFICANCE

Herein, we have for the first time developed a scaffold-free parathyroid tissue spheroids using differentiated tonsil-derived mesenchymal stem cells (dTMSC) to restore in vivo parathyroid cell functions. This new strategy is effective, even for long periods (3months), and is thus likely to be more feasible in clinic for hypoparathyroidism treatment. Development of TMSC spheroids may also provide a convenient and efficient scaffold-free platform for researchers investigating conditions involving abnormal calcium homeostasis, such as osteoporosis.

摘要

未标注

为恢复受损的甲状旁腺功能,甲状旁腺组织工程是最佳选择。此前,我们报道分化的扁桃体来源间充质干细胞(dTMSC)可恢复体内甲状旁腺功能,但前提是将它们嵌入支架中。然而,由于基质胶的生物相容性有限,在此我们开发了一种更具临床适用性的无支架甲状旁腺再生系统。无支架dTMSC球体在前7天于由聚二甲基硅氧烷制成的凹形微孔板中在对照培养基中构建,接下来7天在分化培养基(含激活素A和音猬因子)中培养。dTMSC球体的大小在第5天前呈现逐渐且显著的减小,此后减小幅度小得多。dTMSC球体中的细胞具有高活力(>80%)。它们高水平表达完整甲状旁腺激素(iPTH)、甲状旁腺分泌蛋白1和细胞黏附分子N-钙黏蛋白。此外,与接受载体或未分化TMSC球体治疗的甲状旁腺切除(PTX)大鼠相比,植入dTMSC球体的PTX大鼠在3个月期间显示出更高的存活率(50%),血清iPTH(57.7 - 128.2pg/mL)和离子钙(0.70 - 1.15mmol/L)水平均处于生理范围。这是关于无支架、基于人干细胞的甲状旁腺组织工程的首次报道,并且代表了一种比需要支架的方法在治疗甲状旁腺功能减退方面更具临床可行性的策略。

重要性声明

在此,我们首次使用分化的扁桃体来源间充质干细胞(dTMSC)开发了无支架甲状旁腺组织球体以恢复体内甲状旁腺细胞功能。这种新策略是有效的,甚至在长时间(3个月)内有效,因此在临床上治疗甲状旁腺功能减退可能更可行。TMSC球体的开发也可能为研究涉及钙稳态异常情况(如骨质疏松症)的研究人员提供一个方便且高效的无支架平台。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验